The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Official Title: An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Study ID: NCT01088984
Brief Summary: The primary objective of phase 1 of this study is to establish the recommended phase II dose (RP2D). The primary objective of phase 2 of this study is to evaluate the safety and efficacy of bendamustine at the recommended pediatric dose for the treatment of pediatric patients with relapsed or refractory acute leukemia.
Detailed Description:
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Teva Investigational Site 17, Orange, California, United States
Teva Investigational Site 12, San Diego, California, United States
Teva Investigational Site 10, St. Petersburg, Florida, United States
Teva Investigational Site 8, Baltimore, Maryland, United States
Teva Investigational Site 16, Boston, Massachusetts, United States
Teva Investigational Site 9, Detroit, Michigan, United States
Teva Investigational Site 1, Jackson, Mississippi, United States
Teva Investigational Site 5, Kansas City, Missouri, United States
Teva Investigational Site 14, St. Louis, Missouri, United States
Teva Investigational Site 15, New York, New York, United States
Teva Investigational Site 18, Portland, Oregon, United States
Teva Investigational Site 11, Hershey, Pennsylvania, United States
Teva Investigational Site 7, Philadelphia, Pennsylvania, United States
Teva Investigational Site 19, Memphis, Tennessee, United States
Teva Investigational Site 3, Dallas, Texas, United States
Teva Investigational Site 4, Fort Worth, Texas, United States
Teva Investigational Site 13, Houston, Texas, United States
Teva Investigational Site 2, Seattle, Washington, United States
Teva Investigational Site 6, Milwaukee, Wisconsin, United States
Teva Investigational Site 300, Herston, , Australia
Teva Investigational Site 301, Parkville, , Australia
Teva Investigational Site 302, Randwick, , Australia
Teva Investigational Site 520, Minsk, , Belarus
Teva Investigational Site 615, Barretos-SP, , Brazil
Teva Investigational Site 616, Caxias do Sul, , Brazil
Teva Investigational Site 613, Curitiba-PR, , Brazil
Teva Investigational Site 612, Porto Alegre, , Brazil
Teva Investigational Site 614, Porto Alegre, , Brazil
Teva Investigational Site 617, Sao Paulo-SP, , Brazil
Teva Investigational Site 610, Sao Paulo, , Brazil
Teva Investigational Site 611, Sao Paulo, , Brazil
Teva Investigational Site 100, Toronto, , Canada
Teva Investigational Site 501, Jerusalem, , Israel
Teva Investigational Site 503, Petach Tikva, , Israel
Teva Investigational Site 502, Ramat Gan, , Israel
Teva Investigational Site 330, Seoul, , Korea, Republic of
Teva Investigational Site 331, Seoul, , Korea, Republic of
Teva Investigational Site 332, Seoul, , Korea, Republic of
Teva Investigational Site 333, Seoul, , Korea, Republic of
Teva Investigational Site 603, Guadalajara, , Mexico
Teva Investigational Site 600, Mexico City, , Mexico
Teva Investigational Site 601, Mexico City, , Mexico
Teva Investigational Site 602, Monterrey, , Mexico
Teva Investigational Site 303, Auckland, , New Zealand
Teva Investigational Site 531, Bialystok, , Poland
Teva Investigational Site 530, Lublin, , Poland
Teva Investigational Site 532, Warszawa, , Poland
Teva Investigational Site 511, Moscow, , Russian Federation
Teva Investigational Site 510, St. Petersburg, , Russian Federation
Teva Investigational Site 320, Singapore, , Singapore
Name: Sponsor's Medical Expert
Affiliation: Cephalon
Role: STUDY_DIRECTOR